Loading...
•
Mar 31, 2021
Royalty Pharma Q1 2021 Earnings Report
Reported strong operating cash flow and top-line growth driven by the cystic fibrosis franchise.
Key Takeaways
Royalty Pharma reported a 14% increase in total income and other revenues to $573 million, driven by growth from the cystic fibrosis franchise. Adjusted Cash Receipts increased 37% to $524 million and Adjusted Cash Flow grew 37% to $409 million.
Net cash provided by operating activities increased 12% to $526 million.
Total income and other revenues grew 14% to $573 million, driven by growth from the cystic fibrosis franchise.
Adjusted Cash Receipts increased 37% to $524 million.
Adjusted Cash Flow grew 37% to $409 million.
Revenue by Segment
Forward Guidance
Royalty Pharma anticipates full-year 2021 Adjusted Cash Receipts to be between $1,940 million and $1,980 million, excluding new transactions announced subsequent to the date of this release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...